Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts

Dimitra Kerdidani(Alexander Fleming Biomedical Sciences Research Center), Maria Tsoumakidou(National and Kapodistrian University of Athens)

bioRxiv (Cold Spring Harbor Laboratory)

March 25, 2020

10.1101/2020.03.24.005355

Cited by 2

Related Papers

Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts.

|Research Square|2021|0